Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2013, Article ID 736085, 10 pages
http://dx.doi.org/10.1155/2013/736085
Research Article

Inhibitory Effect of Matrine on Blood-Brain Barrier Disruption for the Treatment of Experimental Autoimmune Encephalomyelitis

1Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China
2Department of Neurology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China
3Department of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA

Received 2 May 2013; Accepted 22 July 2013

Academic Editor: Andrew MacLean

Copyright © 2013 Su Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. S. Rommer and O. Stüve, “Management of secondary progressive multiple sclerosis: prophy- lactic treatment-past, present, and future aspect,” Current Treatment Options in Neurology, vol. 15, no. 3, pp. 241–258, 2013. View at Google Scholar
  2. H. Lassmann, “Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models,” Experimental Neurology, vol. 225, no. 1, pp. 2–8, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. A. H. Badawi, P. Kiptoo, W.-T. Wang et al., “Suppression of EAE and prevention of blood-brain barrier breakdown after vaccination with novel bifunctional peptide inhibitor,” Neuropharmacology, vol. 62, no. 4, pp. 1874–1881, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. F. Pfeiffer, J. Schäfer, R. Lyck et al., “Claudin-1 induced sealing of blood-brain barrier tight junctions ameliorates chronic experimental autoimmune encephalomyelitis,” Acta Neuropathologica, vol. 122, no. 5, pp. 601–614, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. L. Sorokin, “The impact of the extracellular matrix on inflammation,” Nature Reviews Immunology, vol. 10, no. 10, pp. 712–723, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Agrawal, P. Anderson, M. Durbeej et al., “Dystroglycan is selectively cleaved at the parenchymal basement membrane at sites of leukocyte extravasation in experimental autoimmune encephalomyelitis,” Journal of Experimental Medicine, vol. 203, no. 4, pp. 1007–1019, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. B. T. Hawkins and T. P. Davis, “The blood-brain barrier/neurovascular unit in health and disease,” Pharmacological Reviews, vol. 57, no. 2, pp. 173–185, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. G. F. Hamann, M. Liebetrau, H. Martens et al., “Microvascular basal lamina injury after experimental focal cerebral ischemia and reperfusion in the rat,” Journal of Cerebral Blood Flow & Metabolism, vol. 22, no. 5, pp. 526–533, 2002. View at Google Scholar
  9. F. A. Sehba, G. Mostafa, J. Knopman, V. Friedrich Jr., and J. B. Bederson, “Acute alterations in microvascular basal lamina after subarachnoid hemorrhage,” Journal of Neurosurgery, vol. 101, no. 4, pp. 633–640, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. J. Liu, X. Jin, K. J. Liu, and W. Liu, “Matrix metalloproteinase-2-mediated occludin degradation and caveolin-1-mediated claudin-5 redistribution contribute to blood-brain barrier damage in early ischemic stroke stage,” Journal of Neuroscience, vol. 32, no. 9, pp. 3044–3057, 2012. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Khan, T. S. Dhammu, H. Sakakima et al., “The inhibitory effect of S-nitroso-glutathione on blood-brain barrier disruption and peroxynitrite formation in a rat model of experimental stroke,” Journal of Neurochemistry, vol. 123, no. 2, pp. 86–97, 2012. View at Google Scholar
  12. J. Bennett, J. Basivireddy, A. Kollar et al., “Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE,” Journal of Neuroimmunology, vol. 229, no. 1-2, pp. 180–191, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. S. M. Gold, M. V. Sasidhar, L. B. Morales et al., “Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERα),” Laboratory Investigation, vol. 89, no. 10, pp. 1076–1083, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. L. D. Kandagaddala, M.-J. Kang, B. C. Chung, T. A. Patterson, and O.-S. Kwon, “Expression and activation of matrix metalloproteinase-9 and NADPH oxidase in tissues and plasma of experimental autoimmune encephalomyelitis in mice,” Experimental and Toxicologic Pathology, vol. 64, no. 1-2, pp. 109–114, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. A. W. Clark, C. A. Krekoski, S.-S. Bou, K. R. Chapman, and D. R. Edwards, “Increased gelatinase A (MMP-2) and gelatinase B (MMP-9) activities in human brain after focal ischemia,” Neuroscience Letters, vol. 238, no. 1-2, pp. 53–56, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. X. Ma, Y. Jiang, A. Wu et al., “Berberine attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice,” PLoS One, vol. 5, no. 10, Article ID e13489, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Avolio, M. Filippi, C. Tortorella et al., “Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment,” Multiple Sclerosis, vol. 11, no. 4, pp. 441–446, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Thorne, C. S. Moore, and G. S. Robertson, “Lack of TIMP-1 increases severity of experimental autoimmune encephalomyelitis: effects of darbepoetin alfa on TIMP-1 null and wild-type mice,” Journal of Neuroimmunology, vol. 211, no. 1-2, pp. 92–100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. E. Lambert, E. Dassé, B. Haye, and E. Petitfrère, “TIMPs as multifacial proteins,” Critical Reviews in Oncology/Hematology, vol. 49, no. 3, pp. 187–198, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Tency, H. Verstraelen, I. Kroes et al., “Imbalances between matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) in maternal serum during preterm labor,” PLoS One, vol. 7, no. 11, Article ID e49042, 2012. View at Google Scholar
  21. W. H. Lee, J. P. Warrington, W. E. Sonntag, and Y. W. Lee, “Irradiation alters MMP-2/TIMP-2 system and collagen type IV degradation in brain,” International Journal of Radiation Oncology Biology Physics, vol. 82, no. 5, pp. 1559–1566, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. Q. C. Kan, L. Zhu, N. Liu, and G. X. Zhang, “Matrine suppresses expression of adhesion molecules and chemokines as a mechanism underlying its therapeutic effect in CNS autoimmunity,” Immunologic Research, vol. 56, no. 1, pp. 189–196, 2013. View at Google Scholar
  23. X. Zhao, Q. Kan, L. Zhu, and G.-X. Zhang, “Matrine suppresses production of IL-23/IL-17 and ameliorates experimental autoimmune encephalomyelitis,” American Journal of Chinese Medicine, vol. 39, no. 5, pp. 933–941, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Zhang, T. Wang, X. Wen et al., “Effect of matrine on HeLa cell adhesion and migration,” European Journal of Pharmacology, vol. 563, no. 1-3, pp. 69–76, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. Z. Wang, J. Zhang, Y. Wang et al., “Matrine, a novel autophagy inhibitor, blocks trafficking and the proteolytic activation of lysosomal proteases,” Carcinogenesis, vol. 34, no. 1, Article ID 138, p. 128, 2013. View at Google Scholar
  26. X. N. Huang, J. Fu, and W. Z. Wang, “The effects of fasudil on the permeability of the rat blood-brain barrier and blood-spinal cord barrier following experimental autoimmune encephalomyelitis,” Journal of Neuroimmunology, vol. 239, no. 1-2, pp. 61–67, 2011. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Fernández-López, J. Faustino, R. Daneman et al., “Blood-brain barrier permeability is increased after acute adult stroke but not neonatal stroke in the rat,” The Journal of Neuroscience, vol. 32, no. 28, pp. 9588–9600, 2012. View at Google Scholar
  28. W. H. Lee, J. P. Warrington, W. E. Sonntag, and Y. W. Lee, “Irradiation alters MMP-2/TIMP-2 system and collagen type IV degradation in brain,” International Journal of Radiation Oncology Biology Physics, vol. 82, no. 5, pp. 1559–1566, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. S. C. Thal, C. Luh, E. V. Schaible et al., “Volatile anesthetics influence blood-brain barrier integrity by modulation of tight junction protein expression in traumatic brain injury,” PLoS One, vol. 7, no. 12, Article ID e50752, 2012. View at Google Scholar
  30. M. J. Fabis, G. S. Scott, R. B. Kean, H. Koprowski, and D. C. Hooper, “Loss of blood-brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse models,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 13, pp. 5656–5661, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. K. Wosik, R. Cayrol, A. Dodelet-Devillers et al., “Angiotensin II controls occludin function and is required for blood-brain barrier maintenance: relevance to multiple sclerosis,” Journal of Neuroscience, vol. 27, no. 34, pp. 9032–9042, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. D. H. Yang, Z. Y. Ye, Y. J. Xie, X. J. He, W. J. Xu, and W. M. Zhou, “Effect of salvianolate on intestinal epithelium tight junction protein zonula occludens protein 1 in cirrhotic rats,” World Journal of Gastroenterology, vol. 18, no. 47, pp. 7040–7047, 2012. View at Google Scholar
  33. J. Bennett, J. Basivireddy, A. Kollar et al., “Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE,” Journal of Neuroimmunology, vol. 229, no. 1-2, pp. 180–191, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. G. A. Rosenberg, “Matrix metalloproteinases and neuroinflammation in multiple sclerosis,” Neuroscientist, vol. 8, no. 6, pp. 586–595, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. M. D. Sternlicht and Z. Werb, “How matrix metalloproteinases regulate cell behavior,” Annual Review of Cell and Developmental Biology, vol. 17, pp. 463–516, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Yang, E. Y. Estrada, J. F. Thompson, W. Liu, and G. A. Rosenberg, “Matrix metalloproteinase-mediated disruption of tight junction proteins in cerebral vessels is reversed by synthetic matrix metalloproteinase inhibitor in focal ischemia in rat,” Journal of Cerebral Blood Flow and Metabolism, vol. 27, no. 4, pp. 697–709, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. A. T. Bauer, H. F. Bürgers, T. Rabie, and H. H. Marti, “Matrix metalloproteinase-9 mediates hypoxia-induced vascular leakage in the brain via tight junction rearrangement,” Journal of Cerebral Blood Flow and Metabolism, vol. 30, no. 4, pp. 837–848, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Jovanova-Nesic and Y. Shoenfeld, “MMP-2, VCAM-1 and NCAM-1 expression in the brain of rats with experimental autoimmune encephalomyelitis as a trigger mechanism for synaptic plasticity and pathology,” Journal of Neuroimmunology, vol. 181, no. 1-2, pp. 112–121, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Opdenakker, I. Nelissen, and J. Van Damme, “Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis,” Lancet Neurology, vol. 2, no. 12, pp. 747–756, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. J. Sellner, F. Simon, U. Meyding-Lamade, and S. L. Leib, “Herpes-simplex virus encephalitis is characterized by an early MMP-9 increase and collagen type IV degradation,” Brain Research, vol. 1125, no. 1, pp. 155–162, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. R. K. Dore, “How to prevent glucocorticoid-induced osteoporosis,” Cleveland Clinic Journal of Medicine, vol. 77, no. 8, pp. 529–536, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. C. Gennari, “Differential effect of glucocorticoids on calcium absorption and bone mass,” British Journal of Rheumatology, vol. 32, no. 2, pp. 11–14, 1993. View at Google Scholar · View at Scopus
  43. M. K.-S. Leow, D. S.-K. Kwek, A. W.-K. Ng, K.-C. Ong, G. J.-L. Kaw, and L. S.-U. Lee, “Hypocortisolism in survivors of severe acute respiratory syndrome (SARS),” Clinical Endocrinology, vol. 63, no. 2, pp. 197–202, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Minagar, A. H. Maghzi, J. C. McGee, and J. S. Alexander, “Emerging roles of endothelial cells in multiple sclerosis pathophysiology and therapy,” Neurological Research, vol. 34, no. 8, pp. 738–745, 2012. View at Google Scholar